Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines

Kuo Hsiang Chuang, Chiu Min Cheng, Steve R. Roffler, Yu Lin Lu, Shiu Ru Lin, Jaw Yuan Wang, Wen Shyong Tzou, Yu Cheng Su, Bing Mae Chen, Tian Lu Cheng

研究成果: 雜誌貢獻文章同行評審

13 引文 斯高帕斯(Scopus)


Combination therapy can help overcome limitations in the treatment of heterogeneous tumors. In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells. Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo. Dansyl moieties were covalently attached to recombinant β-glucuronidase (βG) and interleukin 2 (IL-2) via a flexible polyethylene glycol) linker to form DNS-PEG-βG and DNS-PEG-IL-2 conjugates. The conjugates displayed enzymatic and splenocyte-stimulatory activities, respectively, that were similar to those of the unmodified proteins. The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells). DNS-PEG-βG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration. Systemic administration of DNS-PEG-IL-2 or DNS-PEG-βG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors. Combination treatment with DNS-PEG-βG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen. These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.

頁(從 - 到)707-714
期刊Bioconjugate Chemistry
出版狀態已發佈 - 5月 2006

ASJC Scopus subject areas

  • 化學 (全部)
  • 有機化學
  • 臨床生物化學
  • 生物化學、遺傳與分子生物學 (全部)
  • 生物化學


深入研究「Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines」主題。共同形成了獨特的指紋。